JNJ-95566692 / J&J - LARVOL DELTA

A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies (clinicaltrials.gov) - P1 | N=340 | Recruiting | Sponsor: Janssen Research & Development, LLC | N=130 ➔ 340 | Trial completion date: Aug 2028 ➔ Oct 2029

Enrollment change • First-in-human • Trial completion date • B Cell Lymphoma • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Mediastinal Large B-Cell Lymphoma • BCL2 • IRF4

95566692LYM1001: Phase 1 First-in-Human Study of JNJ-95566692 in Participants with NHLs (clinicaltrialsregister.eu) - P1 | N=13 | Not yet recruiting | Sponsor: Janssen Cilag International

First-in-human • New P1 trial • Hematological Malignancies • Non-Hodgkin’s Lymphoma • Oncology

A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies (clinicaltrials.gov) - P1 | N=130 | Recruiting | Sponsor: Janssen Research & Development, LLC | N=80 ➔ 130 | Not yet recruiting ➔ Recruiting

Enrollment change • Enrollment open • First-in-human • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies (clinicaltrials.gov) - P1 | N=80 | Not yet recruiting | Sponsor: Janssen Research & Development, LLC

First-in-human • New P1 trial • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology